Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | KIF11 | P52732 | 1/20 | 0.49 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 3/20 | 0.46 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.46 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | TDP2 | O95551 | 2/20 | 0.44 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27346378 | 0.98 | KEAP1 (0.55) | KEAP1ALDH1A1SMN1; SMN2POLBKIF11 | |
| SCHEMBL698855 | 0.85 | KEAP1 (0.70) | KEAP1ALDH1A1SMN1; SMN2POLBKIF11 | |
| SCHEMBL7975302 | 0.81 | HPGD (0.47) | ALDH1A1SMN1; SMN2BRD4HTTNR3C2 | |
| SCHEMBL7179126 | 0.80 | KIF11 (0.66) | ALDH1A1SMN1; SMN2KIF11BRD4HSD17B1 | |
| SCHEMBL5426878 | 0.80 | HSD17B1 (0.55) | KEAP1ALDH1A1SMN1; SMN2KIF11BRD4 | |
| SCHEMBL1488101 | 0.80 | KEAP1 (0.57) | KEAP1ALDH1A1SMN1; SMN2POLBKIF11 | |
| SCHEMBL14805247 | 0.78 | KEAP1 (0.55) | KEAP1ALDH1A1SMN1; SMN2POLBKIF11 | |
| SCHEMBL9865360 | 0.78 | KEAP1 (0.59) | KEAP1ALDH1A1SMN1; SMN2POLBKIF11 | |
| SCHEMBL9307018 | 0.78 | KEAP1 (0.59) | KEAP1ALDH1A1SMN1; SMN2POLBKIF11 | |
| SCHEMBL1488105 | 0.78 | KEAP1 (0.59) | KEAP1ALDH1A1SMN1; SMN2POLBKIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2350090-B1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2015-06-03 | — | — | EP | claimed |
| US-8263606-B2 | Spiro-oxindole compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2012-09-11 | — | — | US | claimed |
| EP-2350090-A2 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | Xenon Pharmaceuticals Inc. (CA) | 2011-08-03 | — | — | EP | claimed |
| US-20100137299-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2010-06-03 | — | — | US | claimed |
| WO-2010045251-A2 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS, INC. (CA) | 2010-04-22 | — | — | WO | claimed |
| EP-2102167-A2 | SUBSTITUTED ARYLPYRAZOLES | Pfizer Limited (GB) | 2009-09-23 | — | — | EP | claimed |
| US-20080176865-A1 | SUBSTITUTED ARYLPYRAZOLES | PFIZER LIMITED (GB) | 2008-07-24 | — | — | US | claimed |
| WO-2008072053-A2 | SUBSTITUTED ARYLPYRAZOLES | PFIZER LIMITED (GB) | 2008-06-19 | — | — | WO | claimed |
| US-20070149550-A1 | 1-aryl-4-cyclopropylpyrazoles with at least one fluorine attached to the cyclopropyl ring; parasiticides; fleas; extended duration of action for at least 28 days | PFIZER INC. (US) | 2007-06-28 | — | — | US | claimed |
| CN-1031051-C | Cycloalkyl-substituted glutaramide antihypertensive agents | PFIZER (US) | 1996-02-21 | — | — | CN | claimed |
| EP-0658169-A1 | DIAMINO ACID DERIVATIVES AS ANTIHYPERTENSIVES | SCHERING CORPORATION (US) | 1995-06-21 | — | — | EP | claimed |
| US-5298492-A | Inhibitors of endopeptidase and treatment of cardiovascular disorders | SCHERING CORPORATION (US) | 1994-03-29 | — | — | US | claimed |
| WO-1994003481-A1 | DIAMINO ACID DERIVATIVES AS ANTIHYPERTENSIVES | SCHERING CORPORATION (US) | 1994-02-17 | — | — | WO | claimed |
| EP-0358398-B1 | CYCLOALKYL-SUBSTITUTED GLUTARAMIDE ANTIHYPERTENSIVE AGENTS | Pfizer Limited (GB) | 1993-03-10 | — | — | EP | claimed |
| CN-1040986-A | The preparation of the glutaramide derivatives of cycloalkyl substituted | PFIZER (US) | 1990-04-04 | — | — | CN | claimed |
| EP-0358398-A1 | Cycloalkyl-substituted glutaramide antihypertensive agents | Pfizer Limited (GB) | 1990-03-14 | — | — | EP | claimed |
| US-11944687-B2 | Carbohydrate conjugate RNA agents and process for their preparation | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-04-02 | — | — | US | disclosed |
| EP-4253395-A2 | PROCESSES FOR THE PREPARATION OF CARBOHYDRATE CONJUGATED RNA AGENTS | Alnylam Pharmaceuticals, Inc. (US) | 2023-10-04 | — | — | EP | disclosed |
| US-4243588-A | CYCLIZING A 2-CHLOROAZETIDINONE WITH LEAD FLUORIDE IN DIMETHYL SULFOXIDE TO OBTAIN THE 4-OXA-2,6-DIAZABICYCLO(3.2.0)HEPTANE | ELI LILLY AND COMPANY (US) | 1981-01-06 | — | — | US | disclosed |
| US-4226986-A | 7-ACYLAMINO-3-HYDROXY-3-CEPHEM COMPOUND, TRIARYL PHOSPHITE DIHALIDE | ELI LILLY AND COMPANY (US) | 1980-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176865-A1 | SUBSTITUTED ARYLPYRAZOLES | CYP3A4, CYP3A43, CYP4B1 | KEAP1 3436/4885ALDH1A1 565/4885SMN1; SMN2 2801/4885 |
| US-20070149550-A1 | 1-aryl-4-cyclopropylpyrazoles with at least one fluorine attached to the cyclopropyl ring; parasiticides; fleas; extended duration of action for at least 28 days | CYP3A43, CYP3A4, CYP2F1 | KEAP1 3844/4885ALDH1A1 559/4885SMN1; SMN2 1163/4885 |
| US-11944687-B2 | Carbohydrate conjugate RNA agents and process for their preparation | RNASE1, IGF2BP1, IGF2BP2 | KEAP1 2604/4885ALDH1A1 1864/4885SMN1; SMN2 488/4885 |
| US-20100137299-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | TRPV3, TRPV1, TRPC3 | KEAP1 836/4885ALDH1A1 1020/4885SMN1; SMN2 289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.